News
-
AstraZeneca today announced the initiation of the Phase 3 ATHLOS and THARROS trials evaluating the effects of Breztri Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI on cardiopulmonary parameters and outcomes (including death) in COPD… Read more . . .
-
MannKind Corporation announced that it recently presented initial data from a meal challenge that was part of the Phase 4 INHALE-3 trial of Afrezza insulin DPI plus basal insulin injections versus standard of care in… Read more . . .
-
Vast Therapeutics has announced the appointments of former Aradigm Senior Medical Director Paul Bruinenberg as Chief Medical Officer and Chris Polage as Medical Director in preparation for clinical development of its ALX1 inhalation solution. Bruinenberg was most recently… Read more . . .
-
Boehringer Ingelheim said that “eligible patients” will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol… Read more . . .
-
Researchers at the University of Western Australia have received a A$500,000 grant from the CUREator biotech incubator for development of the Spritz-OM probiotic nasal spray for the prevention of ear infections in children. The grant… Read more . . .
-
Dry powder inhaler specialist Iconovo announced that the company has received a SEK 680,000 grant from the EU’s Innowwide program that will fund a market study as part of Iconovo’s plans to expand into the… Read more . . .
-
Nocion Therapeutics has announced that it raised $62 million in a Series B funding led by Monograph Capital and Arkin Bio Capital. Proceeds will be used to support a Phase 2b trial of its taplucainium… Read more . . .
-
ARS Pharmaceuticals announced that a Phase 2 trial of Neffy epinephrine nasal spray in patients with chronic spontaneous urticaria demonstrated that 1 mg and 2 mg doses of the intranasal epinephrine both produced statistically significant and clinically… Read more . . .
-
Milestone Pharmaceuticals says that it held a Type A meeting with the FDA following receipt of a Refuse to File letter in December 2023 in response to the company’s NDA for etripamil nasal spray for the… Read more . . .
-
ReCode Therapeutics has announced the initiation of a Phase 1 safety and tolerability study of RCT2100 inhaled CFTR mRNA-based therapy, which the company is developing for cystic fibrosis patients who do not benefit from CFTR… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.